Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
暂无分享,去创建一个
R. Bernards | A. V. D. Van Der Zee | S. de Jong | G. Meersma | G. Wisman | Joseph J. Caumanns | A. van der Zee | M. Jalving | A. Kol | Anne van Wijngaarden | Anne P. van Wijngaarden | A. V. van Wijngaarden | A. V. D. van der Zee
[1] Qiu-lin Tang,et al. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. , 2019, Cancer letters.
[2] G. Mills,et al. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.
[3] M. Hidalgo,et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours , 2018, British Journal of Cancer.
[4] Ka-Kui Chan,et al. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma , 2018, International journal of cancer.
[5] N. Hagiwara,et al. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. , 2018, Cancer letters.
[6] R. Bernards,et al. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors , 2018, Oncogene.
[7] R. Bernards,et al. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma , 2018, Clinical Cancer Research.
[8] Ka-Kui Chan,et al. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. , 2018, International journal of cancer.
[9] Steven B. Neuhauser,et al. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. , 2017, Cancer research.
[10] R. Burger,et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. , 2017, Gynecologic oncology.
[11] J. Tabernero,et al. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer , 2017, Targeted Oncology.
[12] Y. Okuno,et al. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. , 2017, The American journal of pathology.
[13] G. Mills,et al. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response , 2017, Nature Communications.
[14] H. Watari,et al. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma , 2017, British Journal of Cancer.
[15] Ali Bashashati,et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.
[16] L. Poulain,et al. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737 , 2016, Molecular Cancer Therapeutics.
[17] J. Grilley-Olson,et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.
[18] Craig B. Davis,et al. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. , 2016, Gynecologic oncology.
[19] Tomohiko Fukuda,et al. Title Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging , 2018 .
[20] K. Russell,et al. Molecular Profiling of Clear Cell Ovarian Cancers , 2016, International Journal of Gynecologic Cancer.
[21] D. Gómez-Almaguer,et al. Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure , 2016, Hematology.
[22] S. Libutti,et al. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. , 2016, Anticancer research.
[23] A. V. D. Van Der Zee,et al. Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods , 2015, Scientific Reports.
[24] H. Kuramoto,et al. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. , 2015, Gynecologic oncology.
[25] C. Lefebvre,et al. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. , 2015, Cancer cell.
[26] James S. Duncan,et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.
[27] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[28] N. Yanaihara,et al. Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma , 2015, PloS one.
[29] H. Soares,et al. Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance , 2014, Molecular Cancer Therapeutics.
[30] J. Kigawa,et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. , 2014, Oncology reports.
[31] G. Scambia,et al. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma , 2014, Virchows Archiv.
[32] K. Yamaguchi,et al. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway , 2014, Molecular Cancer Therapeutics.
[33] Weiliang Shi,et al. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.
[34] Manuel Hidalgo,et al. Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.
[35] D. Bowtell,et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.
[36] Khin Thway,et al. Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.
[37] S. Kaye,et al. New perspectives on molecular targeted therapy in ovarian clear cell carcinoma , 2013, British Journal of Cancer.
[38] M. Dimon,et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo , 2013, Proceedings of the National Academy of Sciences.
[39] I. Shih,et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. , 2012, Human pathology.
[40] Andrew K Godwin,et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. , 2012, Gynecologic oncology.
[41] R. Bernards,et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition , 2012, Leukemia & lymphoma.
[42] F. Sinicrope,et al. Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1* , 2011, The Journal of Biological Chemistry.
[43] A. Ashworth,et al. Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.
[44] Helen X. Chen,et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.
[45] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[46] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[47] Q. She,et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.
[48] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[49] C. Ng,et al. Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies , 2009, Clinical Cancer Research.
[50] P. Workman,et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 , 2009, Molecular Cancer Therapeutics.
[51] V. Velculescu,et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.
[52] S. Steinberg,et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.
[53] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[54] R. Berkowitz,et al. PTEN expression in clear cell adenocarcinoma of the ovary. , 2006, Gynecologic oncology.
[55] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[56] Huajun Yan,et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.
[57] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[58] J. Kigawa,et al. The PI 3 K / mTOR dual inhibitor NVP-BEZ 235 reduces the growth of ovarian clear cell carcinoma , 2022 .